US4515920A - Synthesis of peptides and proteins - Google Patents
Synthesis of peptides and proteins Download PDFInfo
- Publication number
- US4515920A US4515920A US06/605,308 US60530884A US4515920A US 4515920 A US4515920 A US 4515920A US 60530884 A US60530884 A US 60530884A US 4515920 A US4515920 A US 4515920A
- Authority
- US
- United States
- Prior art keywords
- peptide
- peptides
- group
- amino acid
- functional groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 68
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 29
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 28
- 238000003786 synthesis reaction Methods 0.000 title claims description 20
- 230000015572 biosynthetic process Effects 0.000 title claims description 17
- 125000000524 functional group Chemical group 0.000 claims abstract description 26
- 239000007787 solid Substances 0.000 claims abstract description 12
- 238000010532 solid phase synthesis reaction Methods 0.000 claims abstract description 9
- 239000000758 substrate Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 40
- 150000001413 amino acids Chemical class 0.000 claims description 34
- 125000006850 spacer group Chemical group 0.000 claims description 8
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- 238000005304 joining Methods 0.000 claims description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 96
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
- 229920005989 resin Polymers 0.000 description 34
- 239000011347 resin Substances 0.000 description 34
- 229940024606 amino acid Drugs 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- 239000011324 bead Substances 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 125000003277 amino group Chemical group 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 14
- 239000004793 Polystyrene Substances 0.000 description 13
- 229920002223 polystyrene Polymers 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 12
- -1 4-toluensulfonyl group Chemical group 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 239000007790 solid phase Substances 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 102400000050 Oxytocin Human genes 0.000 description 6
- 101800000989 Oxytocin Proteins 0.000 description 6
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 6
- 229960001723 oxytocin Drugs 0.000 description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- CUNVVZWSABRKAL-ZDUSSCGKSA-N (2r)-3-[(4-methylphenyl)methylsulfanyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC1=CC=C(CSC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C=C1 CUNVVZWSABRKAL-ZDUSSCGKSA-N 0.000 description 2
- VDPOXFVWUYMSLQ-UHFFFAOYSA-N 3,5-bis(aminomethyl)benzoic acid Chemical compound NCC1=CC(CN)=CC(C(O)=O)=C1 VDPOXFVWUYMSLQ-UHFFFAOYSA-N 0.000 description 2
- UENRXLSRMCSUSN-UHFFFAOYSA-N 3,5-diaminobenzoic acid Chemical compound NC1=CC(N)=CC(C(O)=O)=C1 UENRXLSRMCSUSN-UHFFFAOYSA-N 0.000 description 2
- UYEMGAFJOZZIFP-UHFFFAOYSA-N 3,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC(O)=C1 UYEMGAFJOZZIFP-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 238000007265 chloromethylation reaction Methods 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 1
- VVNYDCGZZSTUBC-LURJTMIESA-N (2s)-5-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC(N)=O VVNYDCGZZSTUBC-LURJTMIESA-N 0.000 description 1
- QJCNLJWUIOIMMF-YUMQZZPRSA-N (2s,3s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C QJCNLJWUIOIMMF-YUMQZZPRSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- FWZBPBKAANKOJQ-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenyl]acetic acid Chemical compound OCC1=CC=C(CC(O)=O)C=C1 FWZBPBKAANKOJQ-UHFFFAOYSA-N 0.000 description 1
- NRXDUMDULDHIEA-VIFPVBQESA-N 2-[[(2s)-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]amino]acetic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O NRXDUMDULDHIEA-VIFPVBQESA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- JWMGVHYDCWPFAA-UHFFFAOYSA-N 3,5-bis[(2-aminoacetyl)amino]benzoic acid Chemical compound NCC(=O)NC1=CC(NC(=O)CN)=CC(C(O)=O)=C1 JWMGVHYDCWPFAA-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical group SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYSQDHBALBGHX-YFKPBYRVSA-N N(alpha)-t-butoxycarbonyl-L-asparagine Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(N)=O FYYSQDHBALBGHX-YFKPBYRVSA-N 0.000 description 1
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- CHUCHRCHMNCFBF-UHFFFAOYSA-N benzyl 3-[[3,5-bis[[2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]amino]benzoyl]amino]propanoate Chemical compound C(C)(C)(C)OC(=O)NCC(=O)NC=1C=C(C(=O)NCCC(=O)OCC2=CC=CC=C2)C=C(C=1)NC(CNC(=O)OC(C)(C)C)=O CHUCHRCHMNCFBF-UHFFFAOYSA-N 0.000 description 1
- CANCPUBPPUIWPX-UHFFFAOYSA-N benzyl 3-aminopropanoate Chemical compound NCCC(=O)OCC1=CC=CC=C1 CANCPUBPPUIWPX-UHFFFAOYSA-N 0.000 description 1
- FRHWYVGCFUQMJR-UHFFFAOYSA-N benzyl 3-aminopropanoate;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.NCCC(=O)OCC1=CC=CC=C1 FRHWYVGCFUQMJR-UHFFFAOYSA-N 0.000 description 1
- QIBWNGWEFYSLCM-UHFFFAOYSA-N benzyl 3-aminopropanoate;hydrochloride Chemical compound Cl.NCCC(=O)OCC1=CC=CC=C1 QIBWNGWEFYSLCM-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000011968 lewis acid catalyst Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- BQUPLPRJBSPHGT-UHFFFAOYSA-N n-(2-aminoethyl)-2-bromoacetamide Chemical compound NCCNC(=O)CBr BQUPLPRJBSPHGT-UHFFFAOYSA-N 0.000 description 1
- 239000003958 nerve gas Substances 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- XNOPRXBHLZRZKH-MQYCRUOZSA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1C(CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-MQYCRUOZSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000011949 solid catalyst Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- VAVGQBDUTAHJEI-UHFFFAOYSA-N tert-butyl n-[2-[(2-bromoacetyl)amino]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCNC(=O)CBr VAVGQBDUTAHJEI-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- NRTLTGGGUQIRRT-UHFFFAOYSA-N triethylazanium;bromide Chemical compound [Br-].CC[NH+](CC)CC NRTLTGGGUQIRRT-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
- 229940035670 tuftsin Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/15—Oxytocin or vasopressin; related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/28—Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/31—Linker sequence
Definitions
- This invention relates to improvements in the solid phase synthesis of peptides and proteins.
- the initial procedure has been modified by attaching an activated amino acid by its alpha amino group to the resin support and extending the chain towards the carboxyl end.
- Procedures have also been devised in which a functional group of an amino acid other than the alpha amino group or the carboxyl group has served as the link to the solid support.
- a functional group of an amino acid other than the alpha amino group or the carboxyl group has served as the link to the solid support.
- the vast majority of peptides and proteins that have been synthesized using solid phase technology have followed the original procedure in which the peptide has been extended toward the amino end.
- the procedure is conducted by the following steps:
- Steps 2-4 above are repeated as many times as is necessary to produce the desired product.
- the support carrying the synthesized product is recovered by filtration and thoroughly washed to remove insoluble impurities.
- eleven of the twenty common amino acids bear functional groups that are usually protected during the synthesis with protecting groups which will not interfere with the overall synthesis and can be readily removed when it is desirable to do so.
- the guanidino group of arginine has been protected by the nitro group or the 4-toluensulfonyl group.
- the epsilon amino group of lysine has been protected by the benzyloxylcarbonyl group.
- beta carboxyl group of aspartic acid, the gamma carboxyl group of glutamic acid, the beta hydroxyl groups of serine and threonine, and the phenolic hydroxyl group of tyrosine have been protected by the benzyl group.
- Other protecting groups are known and have been employed to protect the extra functional groups of the named amino acids as well as other polyfunctional amino acids.
- Another important variation is to increase the length of the growing chain by coupling the supported amino acid or peptide with a separately synthesized peptide fragment. Still another is to remove the peptide from the support at an intermediate stage in the synthesis, purify it and then reattach it to the support before continuing the synthesis. They have been extensively utilized to produce large numbers of peptides and proteins. Heretofore, the procedures have been as described above. The desired product has been constructed by growth originated from a single link to the selected support.
- cleavage reaction After the peptide has been assembled on a solid support, it must be removed from the support by a suitable cleavage reaction.
- the choice of the cleavage reagent depends primarily on the bond linking the peptide to the support. But the constituent amino acids of the peptide, the nature of their side chain protecting groups, and the structure of the final derivative desired must also be considered. Peptide removal has been effected by acidolytic or alkaline hydrolysis, aminolysis, alcoholysis and other cleavage methods. Acidolysis is by far the most widely employed procedure.
- a large number of acidolytic reagents are known. These include, for example, bromine-free hydrogen bromide in trifluoracetic acid (TFA) or in acetic acid.
- TFA trifluoracetic acid
- the method of choice for most investigators is liquid hydrogen fluoride and anisole at 0° C. for about one hour.
- a particular advantage of this reagent is that it removes all side chain protecting groups and cleaves the most widely employed anchoring bond in one step.
- the most widely employed anchoring bond for the procedure in which the chain is extended toward the amino end is the ester group in which the carboxyl group of the first amino acid in the chain is attached through a benzyl group on a polystyrene support resin.
- the benzyl group is generated by chloromethylation of polystyrene with chloromethyl methyl ether and a Lewis acid catalyst.
- the first amino acid to be attached to the support is reacted as an amino-protected salt, typically the cesium salt.
- solid supports have been studied and utilized in the solid phase synthetic methods. These include polystyrene cross-linked with divinylbenzene, phenol-formaldehyde resins, cellulose, and silicon.
- the support which has achieved widest acceptance is polystyrene cross-linked with about 1% to 2% divinylbenzene.
- the alpha amine protecting group which has proved to be most useful in solid phase synthesis is the tertiary butyloxycarbonyl group (Boc). This group is readily substituted on the amino group and removed when necessary with minimum disruption of the peptide.
- protecting groups used in conventional peptide syntheses have been successfully employed in solid phase synthesis. These include, for example, benzyloxycarbonyl, triphenylmethyl, tertiary amyloxycarbonyl, furfuroxyloxycarbonyl and 2-nitrophenylsulfonyl.
- the construction of the peptide or protein chains is in accordance with standard solid phase techniques as outlined above.
- the advantage is that the amount of useful product produced can be greatly increased per unit time. Theoretically, it can be doubled, quadrupled, etc. In practice, however, the synthetic procedures of this invention, as with most synthetic procedures, do not proceed with one hundred percent efficiency.
- An important feature of the invention is the selection of the trifunctional molecule. It will contain one functional group through which it will be anchored to the resin, and two functional groups from which the peptides or proteins may be grown. Typically, it will contain a carboxyl group and two amino groups joined to an aliphatic or aromatic moiety. The functional groups normally will be positioned symmetrically, but such placement is not essential. As will be apparent from the above general discussion of solid phase synthesis, it is preferred that the linking molecule be one in which there is a single carboxyl group and two amino groups. However, in special circumstances, it may be desirable to have one amino group and two carboxyl groups. As this description proceeds, it will become apparent that functional groups other than carboxyl and amino groups can be employed.
- linking molecule there is a wide range of choices in selecting the linking molecule.
- One of the simplest linking molecules would be 3,5-diaminobenzoic acid. This molecule could be linked directly to a polystyrene support through a benzyl group generated by chloromethylation of crosslinked polystyrene as described above. This linking molecule, however, is not the molecule of choice for a number of reasons. One is that an aromatic amino group is not as reactive as an aliphatic amino group. Another is that the single carboxyl group does not move the linking molecule far enough away from the support to allow maximum flexibility of reactants. It will be remembered that the volume of a sphere increases as the cube of the radius.
- the further a particular reaction center is from the resin support the more space there is for the reactants, and the less problem with steric hindrance. It is preferable, therefore, to include a spacer molecule between the carboxyl group and the resin and to replace the amino group with an aminomethyl group.
- a compound such as 3,5-bis(aminomethyl)benzoic acid is preferable to its next lower homolog.
- Any of a number of spacer molecules can be used with this compound, for example glycine.
- the glycine can be linked to a polystyrene resin through its alpha-carboxyl group in the conventional manner and to the linking molecule through its alpha-amino group by forming a peptide bond.
- Each of the amino methyl groups can serve as anchors for a growing peptide or protein chain.
- each linking molecule gives rise to two peptides. It will also be apparent that if each peptide is replaced with a 3,5-bis(aminomethyl)benzoic acid moiety, the resulting structure will have the potential of anchoring four peptide chains.
- FIG. 1 shows a type of linking segment joined to two peptides by a benzyl ester group.
- the peptides are joined to the linking molecule by an amide group. If the product of FIG. 1 is treated with liquid hydrogen fluoride in anisole at 0° C., the peptides will cleave from the linking molecule. If the product of FIG. 2 is similarly treated cleavage will occur at the ester link to the resin. The resulting hydrolyzed product will contain two peptides joined by the linking segment.
- FIG. 3. generalizes the structures of FIGS. 1 and 2.
- the linking segment or module of FIG. 1 consists of, reading from left to right, a first unit consisting of identical peptides and identical arms.
- the second unit is a core moiety, in this instance shown as being symmetrically substituted.
- the third unit here called the head, is a spacer segment. It is linked to the fourth unit which may be a solid support resin, through an amide linkage.
- the linking module of FIG. 2 is similar to FIG. 1 except for the identity of the segments comprising the structural units.
- FIG. 2 all of the units except the head and the resin are joined together by amide bonds.
- FIG. 1 all of the units except the peptide and the arm are joined by amide units.
- the joining group which is different from all of the other joining groups is a benzyl ester group which is not stable in the presence of liquid hydrogen fluoride. Amide groups are stable in the presence of the reagent. Therefore, treatment of the products represented by FIG. 1 results in cleavage of the peptides from the linking modules. With the products represented by FIG. 2, however, cleavage occurs at the resin end of the structure.
- linking segment or module can be readily constructed by known reactions from known products. They will also recognize that the various products comprising the respective units can be replaced with equivalent products.
- a solid support bearing benzyl alcohol groups 1.
- each of the products can be replaced with an equivalent product and the same results will be obtained, i.e. a linking segment with three functional units, one for combining with the resin support, the other two as starting points for the synthesis of peptides and proteins.
- the invention therefore comprises a synthetic process for the simultaneous production of two, or a multiple of two, identical peptides or proteins by reacting a trifunctional linking molecule to a resin support through one of the functional groups, synthesizing identical peptide chains by simultaneously reacting identical amino acid or peptide or protein residues with the remaining functional groups, successively reacting the resulting product with additional identical amino acid or peptide residues until the desired peptides are obtained and thereafter separating the peptides from the resin support.
- the peptides can be removed as separate units or as part of a larger molecule containing the trifunctional linking module.
- the invention could be defined as an improvement in the known solid phase method for the synthesis of proteins or amino acids in which an amino acids or peptide residue is first joined to a solid support such as a resin and the desired peptide or protein formed by the stepwise addition of amino acid or peptide residues.
- the improvement comprises initially binding a trifunctional module to the solid support through one of the functional groups and thereafter synthesizing identical peptides or proteins by the stepwise addition of amino acid or peptide residues to each of the remaining pair of functional groups.
- the process can be modified by geometrically increasing the number of functional groups available as substrates for the stepwise addition of amino acid or protein residues to the original trifunctional module.
- the number of available substrate functional groups can be increased to as high as 64.
- module refers to a linking molecule or segment which has three functional groups. It may be separated into several units.
- the core of the module is the basic unit to which head and/or arm units may be added.
- the head unit is a spacer group.
- the module need not include a spacer group, but normally such a group will be present to improve the flexibility of the method for reasons explained above.
- residue refers to that portion of the original molecule which remains at the end of a reaction.
- residue of glycine is the glycyl group.
- residue of Boc-leucylglycine is the Boc-leucylglycyl group.
- Preferred linking modules for use in the practice of this invention are those used to prepare the products shown in FIGS. 1 and 2. Their structures are shown in FIGS. 4 and 5. They are preferred since they are easily prepared from readily available reagents by known processes and may be produced in high yield.
- the methods of this invention may be employed in the same manner as conventional solid phase synthesis. They can be used, for example, to prepare the various peptides and proteins which have been prepared by the earlier methods including, for example, angiotensin I and II, bradykinin, gramicidin, neurotensin, tuftsin, and vasopressin, as well as fragments of such materials as casein, elastin, fibrin and insulin.
- the synthesis of oxytocin is shown in the Examples.
- the synthesis is also useful for the preparation of proteins not present in nature such as betabellin 1, the synthesis of which is shown in Example 8. They can be prepared with or without the kinking segment. These proteins are useful for a variety of practical applications, for example they will serve as carriers for various chemical and biological materials used to detect toxic agents such as nerve gases in the atmosphere or for medicinal agents for oral or parenteral administration.
- betabellin The structure of betabellin is shown in FIG. 7. It consists of two 31-residue chains of amino acids linked through Compound 6 of FIG. 6 (with the Boc groups removed) as the linking segment. In the figure covalent bonds are indicated by the positive signs and hydrogen bonds by the dotted lines.
- each residue required the performance of a series of five synthetic steps, which taken together comprised one synthetic cycle.
- Each synthetic cycle consisted of the following five steps: deprotection, neutralization, coupling, neutralization, coupling.
- the second and fourth steps were the same, as were the third and fifth steps.
- the beads were agitated with a solution of trifluoroacetic acid (10 ml) and dichloromethane (10 ml), filtered, and washed with dichloromethane.
- the beads were agitated with a solution of triethylamine (1 ml) and dichloromethane (9 ml), filtered, and washed with dichloromethane.
- the beads were agitated with a solution of the appropriate Boc-amino acid (6 mmol) in dichloromethane (10 ml) for 10 minutes, without filtering the beads a solution of N,N'-dicyclohexylcarbodiimide (6 mmol) in dichloromethane (5 ml) was added, and the beads were agitated for 4-18 hours, filtered, and washed with dichloromethane.
- the beads were coupled with the N-(tert-butoxycarbonyl) derivative of the next amino acid, starting at the carboxyl terminus of betabellin 1.
- the beads were dried under vacuum to remove all organic solvent and stirred with a solution of anisole (1 ml) and liquid hydrogen fluoride (9 ml) for 30 minutes at 0° C.
- the HF and anisole were evaporated using a water aspirator followed by a vacuum pump.
- the residual beads were washed with diethyl ether and were extracted with trifluoroacetic acid.
- the extract was concentrated under vacuum, diluted with water, and lyophilized.
- the residual material which is crude betabellin 1, is purified by chromatographic and electrophoretic procedures.
- 3,5-Bis(glycinamido)benzoic acid (10 mmol), prepared by the method of Akamatsu and Furiya [J. Biochem. (Japan) 41, 317 (1954)], is added to a mixture of bis(tert-butoxycarbonyl)carbonate (20 mmol) and triethylamine (30 mmol) in tert-butanol (25 ml) and water (25 ml). The mixture is stirred for 1 day, acidified with dilute hydrochloric acid to pH 2, and diluted with ethyl acetate (50 ml). The organic phase is washed with water and evaporated to dryness to give the title acid.
- the mixture is gently tumble agitated for 2 days and filtered.
- the beads are washed with dimethylformamide and dichloromethane. Residual aminomethyl groups are acetylated by shaking the resin with a mixture of acetic anhydride (50 ml) and pyridine (50 ml) for 1 day.
- the beads are washed with dimethylformamide and dichloromethane to give the title resin.
- the mixture is gently tumble agitated for 10 min, a solution of N,N'-dicyclohexylcarbodiimide (40 mmol) in dichloromethane (40 mmol) in dichloromethane (40 ml) is added, and agitation is continued for 2 days.
- the beads are washed with dimethylformamide and dichloromethane and swelled in a mixture of trifluoroactic acid (50 ml) and dichloromethane (50 ml).
- the mixture is gently tumble agitated for 1 hour and filtered.
- the beads are washed with dichloromethane, a solution of triethylamine (10 ml) in dichloromethane (90 ml), and dichloromethane to provide the title resin.
- each residue requires the performance of a series of five synthetic steps, which taken together comprise one synthetic cycle.
- Each synthetic cycle consists of the following five steps: neutralization, coupling, neutralization, coupling, deprotection.
- the first and third steps are the same, as are the second and fourth steps.
- the beads (10 g, 20 mmol of amino groups) are agitated with a solution of triethylamine (10 ml) and dichloromethane (90 ml), filtered, and washed with dichloromethane.
- the beads are agitated with a solution of the appropriate Boc-amino acid (60 mmol) in dichloromethane (100 ml) for 10 minutes; without filtering the beads, a solution of N,N'-dicyclohexylcarbodiimide (60 mmol) in dichloromethane (50 ml) is added; and the beads are agitated for 4 hours, filtered, and washed with dichlorom methane. During deprotection, the beads are agitated with asolution of trifluoroaceticacid (50 ml) and dichloromethane (50 ml), filtered, and washed with dichloromethane.
- N-(tert-butoxycarbonyl)-L-proline N-(tert-butoxycarbonyl)-S-(4-methylbenzyl)-L-cysteine
- N-(tert-butoxycarbonyl)-L-asparagine N-(tert-butoxycarbonyl)L-glutamine
- N-(tert-butoxycarbonyl)-L-isoleucine N-(tert-butoxycarbonyl)-O-(2-bromobenzyloxycarbonyl)-L-tyrosine
- N-(tert-butoxycarbonyl)-S-(4-methylbenzyl)-L-cysteine to furnish the title resin.
- Beads (10 g) of bis[Cys(4-MeBzl)-Tyr(2-BrZ)-Ile-Gln-Asn-Cys(4-MeBzl)-Pro-Leu-Gly-Opa-Gly]Dab-betaAla-resin are mixed with a solution of methanol (50 ml) saturated with gaseous anhydrous ammonia at 40° C. The mixture is sealed in a pressure bottle, stirred for 2 days at room temperature, and evaporated to remove all of the ammonia and methanol. The residue is extracted with dimethyl formamide and the extracts are evaporated underreduced pressure.
- the residue is stirred with a solution of anisole (1 ml) and liquid hydrogen floride (9 ml) for 30 minutes at 0° C.
- the HF and anisole are evaporated using a water aspirator followed by a vacuum pump.
- the residual material which is crude oxytocin in the reduced form, is oxidized to the cyclic disulfide form and purified by chromatographic procedures.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
Solid phase synthesis of peptides and proteins have been improved by the use of a trifunctional segment, one functional group of which is bound to a solid support, the other two functional groups being available as substrates upon which identical proteins are synthesized.
Description
This invention relates to improvements in the solid phase synthesis of peptides and proteins.
The classical synthesis of peptides has used the solution method in which a protected amino acid or peptide fragment has been reacted in solution with another protected amino acid or protected peptide chain. At each step of the synthesis the desired product has been separated from the reaction medium and at least partially purified before continuing to the next step. The procedure is time-consuming and tedious. However, it is capable of producing high-purity products. These procedures have been used to produce oxytocin, insulin, adrenocortocotropin and other proteins.
In 1962, Merrifield introduced the solid phase method of peptide synthesis. In this procedure, the amino acid corresponding to the carboxyl end of a peptide chain was attached to an insoluble support, normally a resin through the alpha carboxyl group and the chain was extended toward the amino end by stepwise coupling of activated amino acid derivatives. Filtration and thorough washing of the solid phase removed soluble by-products and excess reagents but retained the extended peptide chain without loss. After completion of the chain the peptide was removed from the support and purified.
The initial procedure has been modified by attaching an activated amino acid by its alpha amino group to the resin support and extending the chain towards the carboxyl end. Procedures have also been devised in which a functional group of an amino acid other than the alpha amino group or the carboxyl group has served as the link to the solid support. However, the vast majority of peptides and proteins that have been synthesized using solid phase technology have followed the original procedure in which the peptide has been extended toward the amino end. Generally the procedure is conducted by the following steps:
1. Attachment of an amino acid with a protected amino group to a resin support through its carboxyl group.
2. Removal of the protecting group from the amino group.
3. Couple the supported amino acid with a second amino acid in which the amino group is protected, by reaction between the deprotected amino group of the supported amino acid and the carboxyl group of the second amino acid.
4. Removal of the protecting group from the amino group of the second amino acid.
Steps 2-4 above are repeated as many times as is necessary to produce the desired product.
At each stage of the synthesis, the support carrying the synthesized product is recovered by filtration and thoroughly washed to remove insoluble impurities.
As those skilled in the art will be aware, there are many variations of the basic theme. For example, eleven of the twenty common amino acids bear functional groups that are usually protected during the synthesis with protecting groups which will not interfere with the overall synthesis and can be readily removed when it is desirable to do so. For example, the guanidino group of arginine has been protected by the nitro group or the 4-toluensulfonyl group. The epsilon amino group of lysine has been protected by the benzyloxylcarbonyl group. The beta carboxyl group of aspartic acid, the gamma carboxyl group of glutamic acid, the beta hydroxyl groups of serine and threonine, and the phenolic hydroxyl group of tyrosine have been protected by the benzyl group. Other protecting groups are known and have been employed to protect the extra functional groups of the named amino acids as well as other polyfunctional amino acids.
Another important variation is to increase the length of the growing chain by coupling the supported amino acid or peptide with a separately synthesized peptide fragment. Still another is to remove the peptide from the support at an intermediate stage in the synthesis, purify it and then reattach it to the support before continuing the synthesis. They have been extensively utilized to produce large numbers of peptides and proteins. Heretofore, the procedures have been as described above. The desired product has been constructed by growth originated from a single link to the selected support.
After the peptide has been assembled on a solid support, it must be removed from the support by a suitable cleavage reaction. The choice of the cleavage reagent depends primarily on the bond linking the peptide to the support. But the constituent amino acids of the peptide, the nature of their side chain protecting groups, and the structure of the final derivative desired must also be considered. Peptide removal has been effected by acidolytic or alkaline hydrolysis, aminolysis, alcoholysis and other cleavage methods. Acidolysis is by far the most widely employed procedure.
A large number of acidolytic reagents are known. These include, for example, bromine-free hydrogen bromide in trifluoracetic acid (TFA) or in acetic acid. The method of choice for most investigators is liquid hydrogen fluoride and anisole at 0° C. for about one hour. A particular advantage of this reagent is that it removes all side chain protecting groups and cleaves the most widely employed anchoring bond in one step.
The most widely employed anchoring bond for the procedure in which the chain is extended toward the amino end is the ester group in which the carboxyl group of the first amino acid in the chain is attached through a benzyl group on a polystyrene support resin. The benzyl group is generated by chloromethylation of polystyrene with chloromethyl methyl ether and a Lewis acid catalyst. The first amino acid to be attached to the support is reacted as an amino-protected salt, typically the cesium salt.
A wide variety of solid supports have been studied and utilized in the solid phase synthetic methods. These include polystyrene cross-linked with divinylbenzene, phenol-formaldehyde resins, cellulose, and silicon. The support which has achieved widest acceptance is polystyrene cross-linked with about 1% to 2% divinylbenzene.
The alpha amine protecting group which has proved to be most useful in solid phase synthesis is the tertiary butyloxycarbonyl group (Boc). This group is readily substituted on the amino group and removed when necessary with minimum disruption of the peptide. However, practically all the protecting groups used in conventional peptide syntheses have been successfully employed in solid phase synthesis. These include, for example, benzyloxycarbonyl, triphenylmethyl, tertiary amyloxycarbonyl, furfuroxyloxycarbonyl and 2-nitrophenylsulfonyl.
This brief overview of the solid phase synthetic method has been provided to indicate that the procedure is well known and has been intensively studied. Principal emphasis has been on procedures in which the peptide grows towards the amino end. Procedures for extending the peptide toward the carboxyl end have also been extensively studied, but because of inherent disadvantages, such as racemization, have not been as widely employed. Those skilled in the art, however, will immediately recognize from a study of this specification that the improvements described herein are applicable to all types of solid phase peptide syntheses.
The solid phase procedures have proven to be a revolutionary advance in peptide synthesis.
A new method has now been discovered which markedly improves the efficiency of the conventional procedure. In this novel approach to solid phase peptide synthesis two or more peptides or proteins are produced from a trifunctional linking molecule. In the linking molecule one of the functional groups is bound to the resin, either directly or through a spacer group. The other two functional groups serve as anchors for the peptide chains. Alternatively, the other two functional groups can each be joined to a second trifunctional molecule, two functional groups of which can serve as anchors for peptide chains. This type of geometric growth from the single point of attachment to the resin can be repeated any selected number of times such as 4 to 6 times to increase the number of anchors available for peptide chains.
The construction of the peptide or protein chains is in accordance with standard solid phase techniques as outlined above. The advantage is that the amount of useful product produced can be greatly increased per unit time. Theoretically, it can be doubled, quadrupled, etc. In practice, however, the synthetic procedures of this invention, as with most synthetic procedures, do not proceed with one hundred percent efficiency.
An important feature of the invention is the selection of the trifunctional molecule. It will contain one functional group through which it will be anchored to the resin, and two functional groups from which the peptides or proteins may be grown. Typically, it will contain a carboxyl group and two amino groups joined to an aliphatic or aromatic moiety. The functional groups normally will be positioned symmetrically, but such placement is not essential. As will be apparent from the above general discussion of solid phase synthesis, it is preferred that the linking molecule be one in which there is a single carboxyl group and two amino groups. However, in special circumstances, it may be desirable to have one amino group and two carboxyl groups. As this description proceeds, it will become apparent that functional groups other than carboxyl and amino groups can be employed.
In all applications of this invention it will be necessary to remove the final product from the resin support. In some procedures it will be desirable to remove the linking segment from the peptide or protein chains. In others it will not be necessary to do so.
It will be apparent, therefore, that there is a wide range of choices in selecting the linking molecule. One of the simplest linking molecules would be 3,5-diaminobenzoic acid. This molecule could be linked directly to a polystyrene support through a benzyl group generated by chloromethylation of crosslinked polystyrene as described above. This linking molecule, however, is not the molecule of choice for a number of reasons. One is that an aromatic amino group is not as reactive as an aliphatic amino group. Another is that the single carboxyl group does not move the linking molecule far enough away from the support to allow maximum flexibility of reactants. It will be remembered that the volume of a sphere increases as the cube of the radius. Therefore, the further a particular reaction center is from the resin support, the more space there is for the reactants, and the less problem with steric hindrance. It is preferable, therefore, to include a spacer molecule between the carboxyl group and the resin and to replace the amino group with an aminomethyl group. Thus a compound such as 3,5-bis(aminomethyl)benzoic acid is preferable to its next lower homolog. Any of a number of spacer molecules can be used with this compound, for example glycine. The glycine can be linked to a polystyrene resin through its alpha-carboxyl group in the conventional manner and to the linking molecule through its alpha-amino group by forming a peptide bond. Each of the amino methyl groups can serve as anchors for a growing peptide or protein chain.
The foregoing discussion can be illustrated by the following structure where R is the resin support. ##STR1##
It will be apparent from the foregoing discussion and structural formula that each linking molecule gives rise to two peptides. It will also be apparent that if each peptide is replaced with a 3,5-bis(aminomethyl)benzoic acid moiety, the resulting structure will have the potential of anchoring four peptide chains.
When peptides grown on the structure shown above are treated with liquid hydrogen fluoride in anisole at 0° C. for one hour, the complete molecule including the linking molecule and the spacer will cleave from the resin. If it is desirable to separate the peptides from the linking molecule the two must be joined by a linkage other than a peptide bond.
The foregoing rather specific discussion should assist in understanding the invention. There follows a more generalized discussion which will illustrate more fully the scope of the invention. The discussion will be assisted by reference to FIGS. 1, 2 and 3.
FIG. 1 shows a type of linking segment joined to two peptides by a benzyl ester group. In FIG. 2 the peptides are joined to the linking molecule by an amide group. If the product of FIG. 1 is treated with liquid hydrogen fluoride in anisole at 0° C., the peptides will cleave from the linking molecule. If the product of FIG. 2 is similarly treated cleavage will occur at the ester link to the resin. The resulting hydrolyzed product will contain two peptides joined by the linking segment.
FIG. 3. generalizes the structures of FIGS. 1 and 2.
The linking segment or module of FIG. 1 consists of, reading from left to right, a first unit consisting of identical peptides and identical arms. The second unit is a core moiety, in this instance shown as being symmetrically substituted. The third unit, here called the head, is a spacer segment. It is linked to the fourth unit which may be a solid support resin, through an amide linkage.
The linking module of FIG. 2 is similar to FIG. 1 except for the identity of the segments comprising the structural units.
It will be noted that in FIG. 2 all of the units except the head and the resin are joined together by amide bonds. In FIG. 1 all of the units except the peptide and the arm are joined by amide units. In both figures the joining group which is different from all of the other joining groups is a benzyl ester group which is not stable in the presence of liquid hydrogen fluoride. Amide groups are stable in the presence of the reagent. Therefore, treatment of the products represented by FIG. 1 results in cleavage of the peptides from the linking modules. With the products represented by FIG. 2, however, cleavage occurs at the resin end of the structure.
Those skilled in the art will immediately recognize that the linking segment or module can be readily constructed by known reactions from known products. They will also recognize that the various products comprising the respective units can be replaced with equivalent products.
The products from which the molecule of FIG. 1 may be synthesized are, reading from right to left:
1. An amino substituted support resin.
2. Glycine
3. 3,5-Diaminobenzoic acid
4. Glycine
5. 4-(Hydroxymethyl)phenylacetic acid
6. Peptide.
The products from which the molecule of FIG. 2 may be synthesized are, reading from right to left:
1. A solid support bearing benzyl alcohol groups.
2. Beta-alanine
3. 3-5-Dihydroxybenzoic acid
4. [(2-Aminoethyl)amino]carbonylmethyl bromide.
5. Peptide
Quite clearly each of the products can be replaced with an equivalent product and the same results will be obtained, i.e. a linking segment with three functional units, one for combining with the resin support, the other two as starting points for the synthesis of peptides and proteins. The invention therefore comprises a synthetic process for the simultaneous production of two, or a multiple of two, identical peptides or proteins by reacting a trifunctional linking molecule to a resin support through one of the functional groups, synthesizing identical peptide chains by simultaneously reacting identical amino acid or peptide or protein residues with the remaining functional groups, successively reacting the resulting product with additional identical amino acid or peptide residues until the desired peptides are obtained and thereafter separating the peptides from the resin support. As shown above, the peptides can be removed as separate units or as part of a larger molecule containing the trifunctional linking module.
More specifically, the invention could be defined as an improvement in the known solid phase method for the synthesis of proteins or amino acids in which an amino acids or peptide residue is first joined to a solid support such as a resin and the desired peptide or protein formed by the stepwise addition of amino acid or peptide residues. The improvement comprises initially binding a trifunctional module to the solid support through one of the functional groups and thereafter synthesizing identical peptides or proteins by the stepwise addition of amino acid or peptide residues to each of the remaining pair of functional groups.
As explained above the process can be modified by geometrically increasing the number of functional groups available as substrates for the stepwise addition of amino acid or protein residues to the original trifunctional module. By this procedure the number of available substrate functional groups can be increased to as high as 64.
The term "module" as used herein refers to a linking molecule or segment which has three functional groups. It may be separated into several units. The core of the module is the basic unit to which head and/or arm units may be added. The head unit is a spacer group. The module need not include a spacer group, but normally such a group will be present to improve the flexibility of the method for reasons explained above.
The term "residue" as applied to amino acids or peptides refers to that portion of the original molecule which remains at the end of a reaction. For example, the residue of glycine is the glycyl group. The residue of Boc-leucylglycine is the Boc-leucylglycyl group.
Preferred linking modules for use in the practice of this invention are those used to prepare the products shown in FIGS. 1 and 2. Their structures are shown in FIGS. 4 and 5. They are preferred since they are easily prepared from readily available reagents by known processes and may be produced in high yield.
The methods of this invention may be employed in the same manner as conventional solid phase synthesis. They can be used, for example, to prepare the various peptides and proteins which have been prepared by the earlier methods including, for example, angiotensin I and II, bradykinin, gramicidin, neurotensin, tuftsin, and vasopressin, as well as fragments of such materials as casein, elastin, fibrin and insulin. The synthesis of oxytocin is shown in the Examples. The synthesis is also useful for the preparation of proteins not present in nature such as betabellin 1, the synthesis of which is shown in Example 8. They can be prepared with or without the kinking segment. These proteins are useful for a variety of practical applications, for example they will serve as carriers for various chemical and biological materials used to detect toxic agents such as nerve gases in the atmosphere or for medicinal agents for oral or parenteral administration.
The structure of betabellin is shown in FIG. 7. It consists of two 31-residue chains of amino acids linked through Compound 6 of FIG. 6 (with the Boc groups removed) as the linking segment. In the figure covalent bonds are indicated by the positive signs and hydrogen bonds by the dotted lines.
The following non-limiting examples are given by way of illustration only. The syntheses described in Examples 1 through 6 are shown in FIG. 6.
Melting points were determined between glass cover slips with a Fisher-Johns apparatus and are uncorrected. Thin-layer chromatograph (TLC) was carried out on glass plates coated with an 0.25-mm layer of silica gel GF (Analtech, Newark, (Del.). IR spectra were measured in CHCL3 solution with a Perkin-Elmer Model 237 grating spectrometer. Proton NMR spectra were taken in CDCL3 or methyl sulfoxide d6 solution at 60 MHz with a Nicolet 7T spectrometer. Chemical shifts are reported in parts per million downfield from internal tetramethylsilane.
A solution of ethylenediamine (50 g, 0.92 mol) in 200 ml of 4-dioxane and 100 ml of water was cooled to 0° C. and bis(tert-butoxycarbonyl)carbonate (50 g, 0.23 mol) was added. The reaction mixture was stored at room temperature for eighteen hours, and the solvent was evaporated. The oily residue was dissolved in a 200 ml ethyl acetate-100 ml water mixture. The ethyl acetate solution was washed with water until TLC showed the absence of ethylenediamine and kept at 0° C. for 18 hours. A second crop of di-Boc compound crystallized out and was filtered off. The filtrate was evaporated and the residual oil dissolved in water (100 ml) and extracted with ethyl acetate twice. The water layer was evaporated in vacuo to give Compound 1 as an oil. The original aqueous layer above was evaporated, the residue was dissolved in ethyl acetate and washed with water to remove the ethylenediamine. The combined organic phase was dried and evaporated in vacuo to provide compound 1. The combined yield of Compound 1 was 15 g (40% yield) as an oil:
(NMR (CDCl3) 1.5 (s,9H), 2.8 (m,2H) 3.2 (q,2H), 5.5 ppm (m,3H).
A solution of Compound 1 (10.4 g, 81 mmol) and triethylamine (8.14 g, 81 mmol) in tetrahydrofuran (200 ml) was cooled to -78° C. A solution of bromacetylbromide (16.3 g, 81 mmol) in tetrahydrofuran (10 ml) was cooled to -78° C. and added dropwise over 15 minutes. The mixture was stirred for 1 hour at -78° C. and another 2 hours at room temperature. The triethylamine hydrobromide salt was filtered off and washed with THF and the combined THF solutions were evaporated. The residue was dissolved in ethyl acetate (500 ml). The solution was washed with ice-cold 0.5N HCl and saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, and evaporated. The residue was triturated with hexane and recrystallized from ethyl acetate and hexane to provide compound 2 as a white powder: 15.6% (77% yield). mp 88°-89° C.; IR (CHCl3) 3500, 1700 and 1680 cm-1 ; NMR (CDCl3) 1.5 (s,9H), 3.4 (t,4H), 3.9 (s,2H), 5.0 (m,1H), and 7.2 ppm (m,1H); Calcd for C9 H17 O3 ; C, 38.44; H, 6.096; N, 9.96; Found: C, 38.41; H, 6.11; N, 9.83.
A solution of beta-alanine (17.8 g, 0.2 mol), 4-toluenesulfonic acid hydrate (46 g, 0.24 mol), and benzyl alcohol (62 ml, 0.6 mol) in benzene (40 ml) was place in a Dean Stark azeotropic distillation apparatus and allowed to reflux for 10 hours. The reaction mixture was cooled to room temperature and the solid residue was mixed with ether and filtered. The solid was washed with ether and with hot ethyl acetate to provide compound 3: 65 g (93% yield).
A solution of 3,5-dihydroxybenzoic acid (4 g, 26 mmol) and N-methylmorpholine (26 mmol) in dimethylformamide (100 ml) was cooled to 0° C. Isobutyl chloroformate (26 mmol) was cooled to 0° C. and added, and the resulting slurry was stirred for 30 minutes. A solution of beta alanine benzyl ester tosylate (26 mmol) and N-methylmorpholine (26 mmol) in dimethylformamide (30 ml) was cooled to 0° C. and added. The reaction mixture was stirred for 18 hours and evaporated under vacuum. The residue was dissolved in ethyl acetate and the solution was washed with 0.5N HCl, saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate and evaporated to provide compound 4 as an oil: 6.0 g (73% yield) IR (CHCl3) 3300, 1710 and 1600 cm-1 ; NMR (CDCl3) 2.8 (t,2H), 3.7 (q,2H), 5.2 (s,2H), 6.6 (t.,1H) 6.9 (d,2H), 7.4 (s,5H), and 7.9 ppm (t,1H); Calcd for C17 H17 O5 N: C, 64.75; H, 5.43; N, 4.44; Found: C, 64.65; H, 5.60; N, 4.24.
A solution of 5-3[dihydroxybenzamido]propionate (1.0 g, 3.17 mmol), potassium fluoride (3.68 g, 63.4 mmol) and N-bromoacetyl-N'-boc-ethylenediamine (1.78 g, 6.34 mmol) in 25 ml of dimethyl formamide was stirred at 50° C. for 1 day. Additional bromo compound (0.356 g, 1.26 mmol) was added and the mixture stirred another day. The progress of the reaction was followed by TLC (CHCl3 :CH3 OH:HOAc 9:1:0.1 by volume). The slurry was cooled to room temperature and evaporated under reduced pressure. The residue was dissolved in ethyl acetate (50 ml) and water (50 ml). The organic phase was washed twice with 50 ml portions of aqueous sodium chloride, dried over anhydrous magnesium sulfate and evaporated. The crude crystals (2.61 g) were recrystallized from ethyl acetate to provide pure compound 5 as a white powder: 1.68 g (74% yield); mp 151°-152° C.; TLC Rf 0.64 (CHCl3 CH3 OH/HOAc 85:10:5); IR (CHCl3) 3450, 2900, 1700 and 1685 cm-1); MS (m/e) 715.3431; Calcd for C35 H49 O11 N5 : C, 58.73; H, 6.89; N, 9.78; Found: C, 58.70; H, 6.88; N, 9.64.
Compound 5 (2 g, 2.8 mmol) was dissolved in methanol (10 ml) and acetic acid (10 ml). To this was added 10% palladium on charcoal (0.5 g) suspended in water (2 ml). Ammonium formate (1 g) was dissolved in a minimum amount of water and added to the slurry. The reaction mixture was stirred for 18 hours at room temperature. The catalyst was filtered off and washed thoroughly with methanol. The filtrate was evaporated to dryness and the residue dissolved in ethyl acetate. The solution was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and evaporated. The residue was recrystallized from ethyl acetate and hexane to provide compound 6 as a white powder: 1.179 (66.8% yield); mp 158°-159° C.; TLC Rf 0.35 (CHCl3 /CH3 OH//HOAc); Calced for C28 H43 O11 N5 : C, 53.75; H, 6.92; N, 11.19; Found C, 53.55; H, 7.06; N, 11.10.
A solution of Compound 6 (2 mmol) and N,N'-dicyclohexylcarbodiimide (2 mmol) in dichloromethane (15 ml) was added to beads of 1-amino-1-phenylmethyl-copoly(styrene-1% divinylbenzene) (1.0 g, 0.5 mmol of amino groups). The mixture was agitated for 2 days, filtered, and washed with dichloromethane. Then the 31 amino acid residues in each of the two chains of betabellin (see FIG. 7 were assembled on the linking segment starting with the carboxyl terminus by the repetitive methodology of solid phase peptide synthesis. The addition of each residue required the performance of a series of five synthetic steps, which taken together comprised one synthetic cycle. Each synthetic cycle consisted of the following five steps: deprotection, neutralization, coupling, neutralization, coupling. Thus, the second and fourth steps were the same, as were the third and fifth steps. During deprotection, the beads were agitated with a solution of trifluoroacetic acid (10 ml) and dichloromethane (10 ml), filtered, and washed with dichloromethane. During neutralization, the beads were agitated with a solution of triethylamine (1 ml) and dichloromethane (9 ml), filtered, and washed with dichloromethane. During coupling, the beads were agitated with a solution of the appropriate Boc-amino acid (6 mmol) in dichloromethane (10 ml) for 10 minutes, without filtering the beads a solution of N,N'-dicyclohexylcarbodiimide (6 mmol) in dichloromethane (5 ml) was added, and the beads were agitated for 4-18 hours, filtered, and washed with dichloromethane. During each synthetic cycle, the beads were coupled with the N-(tert-butoxycarbonyl) derivative of the next amino acid, starting at the carboxyl terminus of betabellin 1. After assembly of the 31-residue peptide chains on each arm of the linking module was completed, the beads were dried under vacuum to remove all organic solvent and stirred with a solution of anisole (1 ml) and liquid hydrogen fluoride (9 ml) for 30 minutes at 0° C. The HF and anisole were evaporated using a water aspirator followed by a vacuum pump. The residual beads were washed with diethyl ether and were extracted with trifluoroacetic acid. The extract was concentrated under vacuum, diluted with water, and lyophilized. The residual material, which is crude betabellin 1, is purified by chromatographic and electrophoretic procedures.
3,5-Bis(glycinamido)benzoic acid (10 mmol), prepared by the method of Akamatsu and Furiya [J. Biochem. (Japan) 41, 317 (1954)], is added to a mixture of bis(tert-butoxycarbonyl)carbonate (20 mmol) and triethylamine (30 mmol) in tert-butanol (25 ml) and water (25 ml). The mixture is stirred for 1 day, acidified with dilute hydrochloric acid to pH 2, and diluted with ethyl acetate (50 ml). The organic phase is washed with water and evaporated to dryness to give the title acid.
A solution of 3,5-Bis[N-tert-butoxycarbonyl)glycinamidol]benzoic acid (10 mmol) and N,N'-dicyclohexylcarbodiimide (10 mmol) in dichloromethane (100 ml) is kept at room temperature for 2 hours. A solution of benzyl 3-aminopropionate hydrochloride (10 mmol) and triethylamine (10 ml) in dichloromethane (50 ml) is added. The mixture is stirred for 24 hours and diluted with dilute hydrochloric acid to pH 2. The organic phase is washed with water, saturated aqueous sodium bicarbonate, and water, dried over anhydrous magnesium sulfate, and evaporated to dryness under vacuum to furnish the title ester.
A solution of benzyl 3-[3,5-bis[N2 -(tertbutoxycarbonyl)glycinamido]benzamido]propionate (10 mmol), 88% formic acid (100 mmol), methanol (30 ml), and acetic acid (30 ml) is stirred with 10% palladium on carbon for 1 hour. The solid catalyst is filtered off and the filtrate is evaporated under reduced pressure to yield the title acid.
Aminomethyl-copoly(styrene-1% divinylbenzene) ("resin") beads (10 g, 1.0 mmol. of amino groups per gram of resin, 200-400 mesh), prepared by the procedure of Mitchell, Kent, Erickson & Merrifield [Tetrahedron Lett., 3795(1976)], is swelled in dimethylformamide (80 ml). A solution of 3-[3,5-bis[N-tertbutoxycarbonyl)glycinamido]propionic acid (10 ml) and N,N'-dicyclohexylcarbodiimide (10 mmol) in dimethylformamide (50 ml) is kept at room temperature for 1 hour and added to the swelled resin. The mixture is gently tumble agitated for 2 days and filtered. The beads are washed with dimethylformamide and dichloromethane. Residual aminomethyl groups are acetylated by shaking the resin with a mixture of acetic anhydride (50 ml) and pyridine (50 ml) for 1 day. The beads are washed with dimethylformamide and dichloromethane to give the title resin.
3-[3,5-Bis]N-tert-butoxycarbonyl)glycinamidobenzamido]proprionamidomethyl-polystyrene beads (10 g) are swelled in a mixture of trifluoroacetic acid (50 ml) and dichloromethane (50 ml). The mixture is gently tumble agitated for 1 hour and filtered. The beads are washed with dichloromethane, a solution of triethylamine (10 ml) in dichloromethane (90 ml), and dichloromethane to provide the title resin.
3-[3,5-Bis(glyclamino)benzolyamino]propionamidomethyl]-polystyrene beads (10 g, 20 mmol) are swelled in dichloromethane (70 ml) is added. A solution of 4-[N-(tert-butoxycarbonyl)glycyloxmethyl]phenyl acetic acid, prepared by the procedure of Tam, Kent, Wong & Merrifield [Synthesis 955 (1979)], (40 mmol) in dichloromethane (100 ml). The mixture is gently tumble agitated for 10 min, a solution of N,N'-dicyclohexylcarbodiimide (40 mmol) in dichloromethane (40 mmol) in dichloromethane (40 ml) is added, and agitation is continued for 2 days. The beads are washed with dimethylformamide and dichloromethane and swelled in a mixture of trifluoroactic acid (50 ml) and dichloromethane (50 ml). The mixture is gently tumble agitated for 1 hour and filtered. The beads are washed with dichloromethane, a solution of triethylamine (10 ml) in dichloromethane (90 ml), and dichloromethane to provide the title resin.
The remaining eight amino acids of oxytocin are assembled on the linking segment starting with the carboxyl terminus by the repetetive methodology of solid phase peptide synthesis. The addition of each residue requires the performance of a series of five synthetic steps, which taken together comprise one synthetic cycle. Each synthetic cycle consists of the following five steps: neutralization, coupling, neutralization, coupling, deprotection. Thus, the first and third steps are the same, as are the second and fourth steps. During neutralization, the beads (10 g, 20 mmol of amino groups) are agitated with a solution of triethylamine (10 ml) and dichloromethane (90 ml), filtered, and washed with dichloromethane. During coupling, the beads are agitated with a solution of the appropriate Boc-amino acid (60 mmol) in dichloromethane (100 ml) for 10 minutes; without filtering the beads, a solution of N,N'-dicyclohexylcarbodiimide (60 mmol) in dichloromethane (50 ml) is added; and the beads are agitated for 4 hours, filtered, and washed with dichlorom methane. During deprotection, the beads are agitated with asolution of trifluoroaceticacid (50 ml) and dichloromethane (50 ml), filtered, and washed with dichloromethane. During the first synthetic cycle, 3-[3,5-bis[N2 [4-glycyloxymethyl]phenylacetyl]glycinamidolbenzamido]propionamidomethyl-polystyrene is coupled with N-(tert-butoxycarbonyl)-L-leucine. During the following synthetic cycles the resulting beads are coupled in turn with N-(tert-butoxycarbonyl)-L-proline, N-(tert-butoxycarbonyl)-S-(4-methylbenzyl)-L-cysteine, N-(tert-butoxycarbonyl)-L-asparagine, N-(tert-butoxycarbonyl)L-glutamine, N-(tert-butoxycarbonyl)-L-isoleucine, N-(tert-butoxycarbonyl)-O-(2-bromobenzyloxycarbonyl)-L-tyrosine, and N-(tert-butoxycarbonyl)-S-(4-methylbenzyl)-L-cysteine to furnish the title resin.
Beads (10 g) of bis[Cys(4-MeBzl)-Tyr(2-BrZ)-Ile-Gln-Asn-Cys(4-MeBzl)-Pro-Leu-Gly-Opa-Gly]Dab-betaAla-resin are mixed with a solution of methanol (50 ml) saturated with gaseous anhydrous ammonia at 40° C. The mixture is sealed in a pressure bottle, stirred for 2 days at room temperature, and evaporated to remove all of the ammonia and methanol. The residue is extracted with dimethyl formamide and the extracts are evaporated underreduced pressure. The residue is stirred with a solution of anisole (1 ml) and liquid hydrogen floride (9 ml) for 30 minutes at 0° C. The HF and anisole are evaporated using a water aspirator followed by a vacuum pump. The residual material, which is crude oxytocin in the reduced form, is oxidized to the cyclic disulfide form and purified by chromatographic procedures.
Claims (4)
1. In the solid phase method for the synthesis of peptides or proteins in which an amino acid or protein is joined to a solid support and the desired peptide or protein is formed by stepwise addition of amino acid or peptide residues to produce the desired peptide or protein, the improvement comprising initially binding a trifunctional module to the solid support through one of its functional groups and thereafter synthesizing two identical peptides or proteins by stepwise addition of amino acid or peptide residues to each of the remaining pair of functional groups.
2. The method of claim 1 in which the original trifunctional module is joined through each of said remaining pair of functional groups to two additional trifunctional modules through one functional group on each molecule and thereafter synthesizing four identical peptides or proteins by stepwise addition of amino acid or peptide residues to each of the remaining two pairs of functional groups.
3. The method of claim 2 including the steps of joining additional pairs of trifunctional modules until the number of functional groups available as substrates for the stepwise addition of amino acids and protein is 8, 16, 32 or 64.
4. The method of claims 1, 2 or 3 in which the module includes a spacer segment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/605,308 US4515920A (en) | 1984-04-30 | 1984-04-30 | Synthesis of peptides and proteins |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/605,308 US4515920A (en) | 1984-04-30 | 1984-04-30 | Synthesis of peptides and proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4515920A true US4515920A (en) | 1985-05-07 |
Family
ID=24423123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/605,308 Expired - Fee Related US4515920A (en) | 1984-04-30 | 1984-04-30 | Synthesis of peptides and proteins |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US4515920A (en) |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4686281A (en) * | 1983-08-29 | 1987-08-11 | Institut Pasteur | Novel synthetic peptide, process for its preparation and medicaments containing it |
| US4704451A (en) * | 1985-10-15 | 1987-11-03 | Washington University | Mitogenic peptides |
| US4749742A (en) * | 1985-07-18 | 1988-06-07 | The Queens's University Of Belfast | Solid phase peptide synthesis |
| US4755558A (en) * | 1986-05-30 | 1988-07-05 | Beckman Instruments, Inc. | Using internal marker |
| US4855486A (en) * | 1986-05-30 | 1989-08-08 | Kalbag Suresh M | Blocked, marked amino acids |
| WO1991004266A1 (en) * | 1989-09-15 | 1991-04-04 | Coselco Mimotopes Pty Ltd. | Solid surface for peptide synthesis |
| US5028593A (en) * | 1989-08-15 | 1991-07-02 | Board Of Regents, The University Of Texas System | Tuftsin analogs |
| US5134071A (en) * | 1989-02-06 | 1992-07-28 | State University Of New York | Polymerization and copolymerization of proteins |
| GB2258236A (en) * | 1991-07-30 | 1993-02-03 | Hitachi Europ Ltd | Molecular synthesis |
| US5229490A (en) * | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| EP0576941A1 (en) * | 1992-06-30 | 1994-01-05 | Nisshin Flour Milling Co., Ltd. | N-benzoylamino acid derivatives, pharmaceutical compositions containing them and process for preparing same |
| WO1994011388A1 (en) * | 1992-11-06 | 1994-05-26 | Chiron Mimotopes Pty. Ltd. | Support for the synthesis of modular polymers |
| US5622934A (en) * | 1991-11-29 | 1997-04-22 | Hoechst Aktiengesellschaft | Peptides with an insulin-like action |
| US5854250A (en) * | 1995-10-11 | 1998-12-29 | Gyogyszerkutato Intezet Kft | N-benzoylamino acid derivatives, pharmaceutical compositions containing them and process of preparing same |
| US6093296A (en) * | 1990-02-28 | 2000-07-25 | Aclara Biosciences, Inc. | Method and device for moving molecules by the application of a plurality of electrical fields |
| WO2002016022A3 (en) * | 2000-08-24 | 2002-08-29 | Febit Ag | Novel strategie for synthesising polymers on surfaces |
| EP1364941A1 (en) * | 2002-05-22 | 2003-11-26 | Applied NanoSystems B.V. | Gelling agents |
| US20070034627A1 (en) * | 2003-05-02 | 2007-02-15 | Richard Roy Wood | Intermediate bulk container |
| WO2009029716A1 (en) | 2007-08-28 | 2009-03-05 | Ramot At Tel Aviv University | Peptides inducing a cd4i conformation in hiv gp120 while retaining vacant cd4 binding site |
| EP2292247A2 (en) | 2002-03-05 | 2011-03-09 | Ramot at Tel Aviv University Ltd. | Immunizing composition and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3956219A (en) * | 1973-02-01 | 1976-05-11 | Eli Lilly And Company | Crosslinked polystyrene and substituted polystyrene compositions |
| US4038469A (en) * | 1973-07-31 | 1977-07-26 | Glaxo Laboratories Limited | Aqueous insoluble polymers containing a plurality of diazomethylene groups |
| US4062746A (en) * | 1975-05-07 | 1977-12-13 | Wisconsin Alumni Research Foundation | Solid phase synthesis of protected peptides |
-
1984
- 1984-04-30 US US06/605,308 patent/US4515920A/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3956219A (en) * | 1973-02-01 | 1976-05-11 | Eli Lilly And Company | Crosslinked polystyrene and substituted polystyrene compositions |
| US4038469A (en) * | 1973-07-31 | 1977-07-26 | Glaxo Laboratories Limited | Aqueous insoluble polymers containing a plurality of diazomethylene groups |
| US4062746A (en) * | 1975-05-07 | 1977-12-13 | Wisconsin Alumni Research Foundation | Solid phase synthesis of protected peptides |
Cited By (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4686281A (en) * | 1983-08-29 | 1987-08-11 | Institut Pasteur | Novel synthetic peptide, process for its preparation and medicaments containing it |
| US4749742A (en) * | 1985-07-18 | 1988-06-07 | The Queens's University Of Belfast | Solid phase peptide synthesis |
| EP0209379A3 (en) * | 1985-07-18 | 1988-08-17 | The Queen's University of Belfast | Solid phase peptide synthesis |
| US4704451A (en) * | 1985-10-15 | 1987-11-03 | Washington University | Mitogenic peptides |
| US4755558A (en) * | 1986-05-30 | 1988-07-05 | Beckman Instruments, Inc. | Using internal marker |
| US4855486A (en) * | 1986-05-30 | 1989-08-08 | Kalbag Suresh M | Blocked, marked amino acids |
| US5229490A (en) * | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| US5134071A (en) * | 1989-02-06 | 1992-07-28 | State University Of New York | Polymerization and copolymerization of proteins |
| US5028593A (en) * | 1989-08-15 | 1991-07-02 | Board Of Regents, The University Of Texas System | Tuftsin analogs |
| WO1991004266A1 (en) * | 1989-09-15 | 1991-04-04 | Coselco Mimotopes Pty Ltd. | Solid surface for peptide synthesis |
| US6093296A (en) * | 1990-02-28 | 2000-07-25 | Aclara Biosciences, Inc. | Method and device for moving molecules by the application of a plurality of electrical fields |
| GB2258236A (en) * | 1991-07-30 | 1993-02-03 | Hitachi Europ Ltd | Molecular synthesis |
| GB2258236B (en) * | 1991-07-30 | 1995-03-22 | Hitachi Europ Ltd | Molecular synthesis |
| US5622934A (en) * | 1991-11-29 | 1997-04-22 | Hoechst Aktiengesellschaft | Peptides with an insulin-like action |
| US5705529A (en) * | 1992-06-30 | 1998-01-06 | Gyogyszerkutato Intezet Kft | N-benzoyl amino acid derivatives pharmaceutical compositions containing them and process for preparing same |
| EP0576941A1 (en) * | 1992-06-30 | 1994-01-05 | Nisshin Flour Milling Co., Ltd. | N-benzoylamino acid derivatives, pharmaceutical compositions containing them and process for preparing same |
| WO1994011388A1 (en) * | 1992-11-06 | 1994-05-26 | Chiron Mimotopes Pty. Ltd. | Support for the synthesis of modular polymers |
| US5854250A (en) * | 1995-10-11 | 1998-12-29 | Gyogyszerkutato Intezet Kft | N-benzoylamino acid derivatives, pharmaceutical compositions containing them and process of preparing same |
| US20040010081A1 (en) * | 2000-08-24 | 2004-01-15 | Ramon Guimil | Novel strategy for synthesizing polymers in surfaces |
| WO2002016022A3 (en) * | 2000-08-24 | 2002-08-29 | Febit Ag | Novel strategie for synthesising polymers on surfaces |
| EP2292247A2 (en) | 2002-03-05 | 2011-03-09 | Ramot at Tel Aviv University Ltd. | Immunizing composition and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein |
| EP1364941A1 (en) * | 2002-05-22 | 2003-11-26 | Applied NanoSystems B.V. | Gelling agents |
| WO2003097587A3 (en) * | 2002-05-22 | 2004-03-11 | Applied Nanosystems Bv | Gelling agents |
| US20050250857A1 (en) * | 2002-05-22 | 2005-11-10 | Van Bommel Kjeld Jacobus Corne | Gelling agents |
| US7645805B2 (en) | 2002-05-22 | 2010-01-12 | Applied Nanosystems, B.V. | Gelling agents |
| US20070034627A1 (en) * | 2003-05-02 | 2007-02-15 | Richard Roy Wood | Intermediate bulk container |
| US8100264B2 (en) | 2003-05-02 | 2012-01-24 | Almar Packaging (Pty) Ltd. | Intermediate bulk container |
| WO2009029716A1 (en) | 2007-08-28 | 2009-03-05 | Ramot At Tel Aviv University | Peptides inducing a cd4i conformation in hiv gp120 while retaining vacant cd4 binding site |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4515920A (en) | Synthesis of peptides and proteins | |
| US4946942A (en) | Urethane-protected amino acid-N-carboxyanhydrides | |
| JP3249178B2 (en) | Solid phase synthesis of peptides containing a C-terminal azaamino acid amide | |
| US4298523A (en) | Methods and compositions for preparation of H-ARG-X-Z-Y-TYR-R | |
| JP2003055396A (en) | Method for rapid solution synthesis of peptides | |
| US5391711A (en) | Biotinylating reagent and purification process for synthesized peptide using thereof | |
| US4250086A (en) | Method and composition for preparation of H-SAR-LYS-SAR-GLN-NH2 | |
| EP1140795A1 (en) | N-3, 3-dimethylbutyl-l-aspartic acid and esters thereof, the process of preparing the same, and the process for preparing n-[n-(3,3-dimethylbutyl)-l-alpha-aspartyl)-l-phenylalanine-1-methylester therefrom | |
| US4290943A (en) | Method of preparing polypeptides | |
| JP3436559B2 (en) | Peptide synthesis method and novel synthetic intermediate | |
| CA2003308A1 (en) | Trialkylsilyl esters of amino acids and their uses in the synthesis of peptides | |
| US4369137A (en) | N-Protected pentapeptides useful as intermediates in the preparation of thymopoietin pentapeptide | |
| US5028693A (en) | Urethane-protected amino acid-N-carboxyanhydrides | |
| USRE29732E (en) | Tripeptide | |
| CA1327868C (en) | Arginine derivative, process for the preparation thereof and its use in peptide synthesis | |
| EP0018793B1 (en) | Peptides and process for their preparation | |
| JP2748897B2 (en) | Novel arginine derivative and method for producing peptide using the same | |
| RU1781226C (en) | Process for producing pyroglutamyl-containing substrates | |
| NO129567B (en) | ||
| JP5982720B2 (en) | Method for producing histidyl-prolinamide derivative using solid polymer support | |
| Miyazawa et al. | Studies of Unusual Amino Acids and Their Peptides. XVII. 1> 2) The Synthesis of Peptides Containing iV-Carboxymethyl Amino Acids. II3, 4) | |
| JPH085812B2 (en) | Method for producing acid amide compound | |
| KR19990071181A (en) | Process for preparing azapeptide derivatives by solid phase reaction | |
| HK1007744B (en) | Urethane-protected amino acid-n-carboxyanhydrides | |
| JPH09255666A (en) | Process for producing piperazine amide compound and piperazine amide derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: ROCKFELLER UNIVERDITY THE, 1230 YORK AVE. NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:ERICKSON, BRUCE W.;REEL/FRAME:004255/0815 Effective date: 19840430 |
|
| REMI | Maintenance fee reminder mailed | ||
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| SULP | Surcharge for late payment | ||
| CC | Certificate of correction | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 19930509 |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |